<DOC>
	<DOCNO>NCT02196324</DOCNO>
	<brief_summary>The purpose study demonstrate whether VPD-737 , NK1 receptor antagonist safe effective treatment prurigo nodularis versus placebo .</brief_summary>
	<brief_title>A Randomized Placebo-Controlled Study Neurokinin-1 ( NK1 ) Receptor Antagonist Serlopitant Prurigo Nodularis ( PN )</brief_title>
	<detailed_description>The sensation itch transmit brain nervous system Several chemical involve transmit signal This trial VPD 737 intend treat condition block one chemical involve transmission itch signal This oral drug administer daily It use trial show safe dos use trial The trial involve daily pill 8 week . Subject ask fill questionnaire electronically paper study period Patients also monitor safety blood take test several point trial Overall participation last 14 week</detailed_description>
	<mesh_term>Prurigo</mesh_term>
	<mesh_term>Neurodermatitis</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<mesh_term>Serlopitant</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Subjects meet follow criterion eligible study entry : 1 . Males female least 18 year 80 year age Screening . 2 . Must PN ( define presence pruritic nodule due chronic pruritus , ) 6 week duration despite treatment current therapy antihistamine corticosteroid ( `` treatment resistant '' PN ) . 3 . Must PN lesion arm , leg , and/or trunk ( ie , lesion must localize ) . 4 . Must VAS pruritus score 70 great within 72 hour Baseline . 5 . Males , nonfecund female ( ie , surgically sterilize , procedure do 12 month screen subject postmenopausal , without menses 12 month screen ) , females childbearing potential use acceptable method birth control period 35 day first dose , female must negative pregnancy test screen baseline visit : Note 1 : Acceptable method birth control include one following : abstinence , vasectomize sexual partner , hormonal method ( ie , birthcontrol pill , hormonal IUD , DepoProvera , implant , patch , intravaginal device [ NuvaRing ] ) , intrauterine device ( IUD [ copper band coil ] ) , diaphragm , cervical cap , condom spermicidal jelly foam . Subjects use oral contraceptive must also use reliable backup method birth control study first menses last dose study medication 14 day menses last dose study medication . 6 . Willing able understand provide write informed consent . 7 . Willing able comply study requirement restriction include discontinuation current therapy pruritus . 8 . Subjects must good health determine medical history , physical examination , result Electro Cardio Gram ( ECG ) clinical laboratory test ( include urinalysis ) . 9 . Agreeing confidential use storage data use anonymized data publication include scientific publication . Subjects eligible study : Have chronic pruritus due condition PN , follow condition : Lichen simplex chronicus Lichen amyloidosus Localized pruritus ( e.g. , one arm affect ) Neuropathic psychogenic pruritus ( notalgia paresthetica , brachioradial pruritus , somatoform prurigo , dilusional parasitosis , depression associate prurigo ) Active dermatosis need immediate therapy atopic dermatitis ( without PN ) bullous pemphigoid ; Have history use ( within specify time period ) medication list . Prior randomization , subject use medication must undergo washout period equal length interval specify ( eg , 2 week antihistamine , 4 week naltrexone , 4 week cyclosporine A ) . Topical systemic antihistamine , ( use ≤2 week prior baseline visit ) [ loratindine , cetirizine may act rescue medication treatment ] ; Topical calcineurin inhibitor , topical capsaicin , menthol , camphor , polidocanol , topical antibiotic , antiseptic bath cleanse lotion ( use ≤2 week prior baseline visit ) ; Topical steroid ( use ≤2 week prior baseline visit ) ; Naltrexone , paroxetine , fluvoxamine , amitriptyline , gabapentin , pregabalin , UVtherapy ( prescribed pruritus treatment ) ( use ≤4 week prior baseline visit ) ; Systemic steroid ( use ≤4 week prior baseline visit ) ; Cyclosporine A immunosuppressant ( use ≤4 week prior baseline visit ) . Have medical condition disability would interfere assessment safety efficacy trial would compromise ability subject undergo study procedure give inform consent . Have chronic acute medical condition , opinion investigator , might interfere study result place subject undue risk . Have history sensitivity component study material . Are females childbearing potential unwilling use adequate contraception breast feeding . Have chronic renal disease , ie , serum creatinine great 2.4 mg/dL . Have aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 2 time upper limit normal . Subjects hepatitis B C normal liver function may enrol . Have current malignancy ( Hodgkin 's lymphoma , B T cell lymphoma , myeloma ) blood cell dyscrasia ( eg , polycythemia myelofibrosis ) might lead systemic chronic pruritus . Subjects untreated hyperthyroidism . Have pruritus psychiatric etiology ( eg , delusion parasitosis , obsessive compulsive disorder , major depression ) neuropathic etiology ( eg , due shingle , spinal cord injury neurologic deficit ) . Have pruritus due urticaria , drug allergy , infection ( pityriasis rosea tinea active human immunodeficiency virus [ HIV ] ) . Note : Subjects HIV undetectable viral load , CD 4 count &gt; 200 cells/cc , stable retroviral therapy may enroll . Are medication know cause pruritus ( ie , Erbitux® , opioids , cocaine , amphetamine , angiotensin convert enzyme [ ACE ] inhibitor ) suspect druginduced pruritus . Have take investigational medication within 30 day prior Screening . Are currently participate clinical study . Have history ( within previous 4 week ) use tricyclic antidepressant , selective serotonin reuptake inhibitor ( SSRI ) , serotoninnorepinephrine reuptake inhibitor ( SNRIS ) , monoamine oxidase ( MAO ) inhibitor , opioids , immunemodulators ( e.g . azathioprine , methotrexate , mycophenolate mofetil , cyclosporine A , antibody ) , neuroactive medication ( e.g . pregabalin , gabapentin ) . Have history ( within previous 4 week ) use sedatives tranquilizer . Subjects must undergo appropriate washout period sedatives tranquilizer enrol study . Are currently treat strong CYP3A4 inhibitor ( e.g . conazole , ketoconazole , fluconazole , itraconazole , voroconazole etc . erythromycin ) . The coadministration moderate CYP3A4 inhibitor VPD737 may allow investigator agreement appropriate safety monitoring . Received ultraviolet B ( UVB ) psoralen + ultraviolet A ( PUVA ) treatment within 30 day prior Screening . Within past 12 month , express suicidal ideation intent act . Started changed cream , emollient include overthecounter ( OTC ) preparation bath oil treatment relief pruritus within 2 week prior Screening . Have social medical condition ( eg , alcoholism , drug dependency , psychotic state ) , investigator 's opinion , might interfere subject 's ability comply requirement protocol . Are employee study site Sponsor 's company .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Prurigo Nodularis</keyword>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Lichen-simplex chronicus</keyword>
</DOC>